Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivuxolimab - Pfizer

Next Previous
Drug Profile

Ivuxolimab - Pfizer

Alternative Names: anti-OX40R-11D4; B110; OX 40; PF-04518600; PF-8600

Latest Information Update: 21 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Dana-Farber Cancer Institute; M. D. Anderson Cancer Center; National Cancer Institute (USA); Pfizer; University of Southern California
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma; Solid tumours; Triple negative breast cancer
  • Phase I/II Acute myeloid leukaemia; Squamous cell cancer
  • No development reported Follicular lymphoma

Most Recent Events

  • 21 Feb 2025 Dana-Farber Cancer Institute terminates a phase Ib trial for Follicular lymphoma (Combination therapy, First-line therapy) in USA (IV) due to drug manufacturer withdrawing supply/funding (NCT03636503)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Follicular lymphoma(Combination therapy, First-line therapy) in USA (IV)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Follicular lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top